World's First Human Spinal Cord Transplant Claimed in Russia Amid Intense Scientific Skepticism

A joint team of Chinese and Russian surgeons claims to have performed the world's first human spinal cord transplant, replacing a damaged section of a paralyzed patient's spinal cord with tissue from a brain-dead donor. The unprecedented 12-hour operation took place at the Sklifosovsky Research Institute for Emergency Medicine in Moscow on October 14 and 15, 2026.[1][2][4]

The experimental procedure was led by Chinese surgeon Ren Xiaoping from the Second Affiliated Hospital of Guangxi University of Chinese Medicine, working alongside Russian medical professionals. The patient, an adult who had sustained a complete spinal cord injury three years earlier, was facing the prospect of permanent immobility before undergoing the surgery.[1][2][5]

Moscow Mayor Sergei Sobyanin publicly announced the surgery on October 16, stating that the patient was in good condition and had been given a chance to recover. However, the surgical team has not yet released peer-reviewed clinical data, detailed neurological assessments, or any concrete evidence of functional recovery.[3][5]

"We have informed the patient of every potential risk and surgical outcome, and the patient's current condition is good," Ren told New Scientist following the procedure. Despite these assurances, the broader medical community remains highly skeptical, warning that surviving a complex surgery does not equate to reversing paralysis.[1][3]

Reconnecting the Nervous System

The central nervous system has a notoriously limited capacity to repair itself, making severe spinal cord injuries a persistent and devastating medical challenge. When the spinal cord is severed, the delicate nerve pathways that carry essential signals between the brain and the rest of the body are permanently disrupted.[4][5]

To bridge the severed gap, the surgical team utilized microsurgery and polyethylene glycol (PEG), a biological glue designed to help damaged cell membranes fuse together. The clinical goal is to create a structural scaffold that encourages the donor tissue to integrate seamlessly with the recipient's existing nervous system.[3][4][5]

While PEG-based repairs have shown some promise in animal models with freshly severed cords, repairing a three-year-old injury introduces immense biological hurdles. Over time, the surrounding bodily systems adapt to the trauma, and the severed nerve fibers lose their natural regenerative potential, making successful fusion significantly more difficult.[3][6]

Independent researchers emphasize that getting transplanted nerve fibers to form working connections across a damaged area is a massive scientific barrier. The donor tissue must also establish a reliable blood supply to survive, while simultaneously avoiding severe rejection by the recipient's immune system.[3][5]

Furthermore, damaged tissues in the spinal cord naturally release nitric oxide to trigger immune responses and aid in initial repair. Unfortunately, this compound is highly neurotoxic, which often exacerbates the damage to the surrounding nervous system and complicates any subsequent surgical interventions aimed at restoring mobility.[3]

Scientific Skepticism and Safety Concerns

The glaring lack of published neurological assessments has prompted intense scrutiny from international neuroscientists and medical ethicists. Melissa Andrews, a neuroscientist at the University of Southampton, questioned the rigor of the underlying animal evidence and highlighted the severe surgical burdens placed on the human patient.[3][6]

Andrews noted that the recipient faces a high risk of infection and life-threatening complications from the extensive 12-hour procedure. With no proof that electrical signals can successfully travel across the transplanted section, many experts view the operation as a highly experimental and unnecessarily risky strategy.[3]

Ren Xiaoping's heavy involvement has also drawn critical attention due to his controversial history in the field of experimental surgery. A decade ago, Ren and Italian neurosurgeon Sergio Canavero gained global notoriety for proposing a human head transplant—a project that faced fierce ethical backlash and never materialized.[1][2][3]

Canavero recently described the Moscow operation as a "Sputnik moment" for spinal cord injury research and regenerative medicine. However, mainstream medical professionals argue that a single unverified case cannot establish safety, effectiveness, or the likelihood of a paralyzed patient ever walking again.[3][5]

The Search for Paralysis Treatments

The World Health Organization estimates that more than 15.4 million people worldwide were living with spinal cord injuries as of 2021. For these patients, the search for a functional cure often involves navigating a complex landscape of experimental treatments, clinical trials, and unproven medical promises.[5]

Rather than relying on high-risk donor tissue, many researchers are focusing on stem cell therapies that use a patient's own cells to safely assist in spinal cord repair. A 2024 review in World Neurosurgery examined 30 registered clinical trials investigating stem cell treatments, though researchers stressed the need for larger multicenter studies.[5]

Stem cell and organoid technologies are advancing rapidly, offering a safer alternative to the severe immune rejection risks associated with donor transplants. By utilizing a patient's own biological material, these targeted therapies aim to stimulate natural nerve regeneration without the need for invasive and dangerous tissue grafting.[3][5]

Digital technology is also demonstrating tangible, peer-reviewed success in bypassing damaged nerve pathways entirely. Recent clinical trials using brain-spine interfaces and targeted electrical stimulation have successfully helped paralyzed patients regain limited movement and muscle strength without the need for complex tissue transplants.[3]

Until the Russian surgical team publishes comprehensive, peer-reviewed data detailing the patient's neurological status, the spinal cord transplant remains an unverified claim. For now, the medical community strongly advises patients to rely on evidence-based rehabilitation rather than pursuing highly experimental surgical interventions.[3][5]